NervGen Pharma Corp. announced a public offering of 24 million common shares and warrants priced at $2.50 each, aiming to raise approximately $60 million before expenses. The funds will support clinical development of its lead neuroreparative drug NVG-291 for spinal cord injury and other neurological conditions. The offering is set to close on May 26, 2026, and is managed by Leerink Partners and TD Cowen. This capital raise is crucial for NervGen to advance its clinical trials and general corporate purposes.
Liminatus Pharma received a delisting notice from Nasdaq due to failure to meet minimum market value requirements for its listed securities and publicly held shares. The company was given until May 18, 2026, to regain compliance but did not meet the ...
Trump Media & Technology Group transferred 2,650 Bitcoin worth about $205 million to Crypto.com, signaling a possible sale amid mounting losses. Earlier in 2026, the company sold 2,000 Bitcoin at around $87,000 each. Originally, TMTG bought 11,542 BT...
Everclear, a cross-chain DeFi clearing protocol, has fully shut down both its protocol and user interface due to revenue challenges. This complete stoppage means users can no longer interact with the system at any level, marking a significant closure...
Ethereum's price briefly rose above the $2,100 level but is now consolidating, showing signs of weakness. This fragile bounce suggests the cryptocurrency may struggle to gain further upward momentum. Investors should be cautious as another selloff co...
Bitcoin Cash (BCH) has been trading within a wide range since April 2024, recently dropping 25% from $465 to $348 after failing to hold the $460 support. Technical indicators like RSI and Stochastic RSI suggest the market is oversold, signaling a pot...
